Corbus Pharmaceuticals Holdings, Inc stock page - price, fundamentals, dividends - iOCharts

CRBP

1.07
+0.05 (4.90%)
Corbus Pharmaceuticals Holdings, Inc (NASDAQ, USD)
Healthcare >
Biotechnology
Market cap
133.79M
Ent value
115.80M
Price/Sales
33.98
Price/Book
1.46
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-61.90%
1 year return
4.90%
3 year return
-47.79%
5 year return
-31.22%
10 year return
-
Last updated: 2021-10-19

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.01
Daily high1.09
Daily low1.01
Daily Volume1.31M
All-time high10.35
1y analyst estimate2.10
Beta1.78
EPS (TTM)-1.13
Dividend per share-
Ex-div date-
Next earnings date8 Nov 2021

Downside potential

Loading...
Downside potential data
CRBPS&P500
Current price drop from All-time high-89.66%-0.56%
Highest price drop-90.92%-56.47%
Date of highest drop30 Oct 20209 Mar 2009
Avg drop from high-46.44%-11.45%
Avg time to new high97 days12 days
Max time to new high1156 days1805 days

DIVIDENDS

CRBP does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales33.98
Price to Book1.46
EV to Sales29.41

FINANCIALS

Per share

Loading...
Per share data
Current share count125.03M
EPS (TTM)-1.13
FCF per share (TTM)-1.01

Income statement

Loading...
Income statement data
Revenue (TTM)3.94M
Gross profit (TTM)3.28M
Operating income (TTM)-122.81M
Net income (TTM)-111.27M
EPS (TTM)-1.13
EPS (1y forward)-0.42

Margins

Loading...
Margins data
Gross margin (TTM)83.28%
Operating margin (TTM)-3119.20%
Profit margin (TTM)-2826.08%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash66.61M
Net receivables2.27M
Total current assets130.29M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment8.88M
Total assets140.15M
Accounts payable21.36M
Short/Current long term debt18.61M
Total current liabilities23.61M
Total liabilities48.63M
Shareholder's equity91.52M
Net tangible assets91.52M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-99.69M
Capital expenditures (TTM)588.66K
Free cash flow (TTM)-100.27M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-245.76%
Return on Assets-108.77%
Return on Invested Capital-173.82%
Cash Return on Invested Capital-156.64%
COMPANY DETAILS
CRBP (Corbus Pharmaceuticals Holdings, Inc) company logo
Marketcap
133.79M
Marketcap category
Small-cap
Description
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Employees
76
Investor relations
SEC filings
CEO
Yuval Cohen
Country
USA
City
Norwood
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
September 10, 2021
The big shareholder groups in Corbus Pharmaceuticals Holdings, Inc. ( NASDAQ:CRBP ) have power over the company...
August 12, 2021
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -25.00% and -83.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock...
August 12, 2021
Company focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endocannabinoid system and integrins into the clinicAugmenting the pipeline through ...
July 29, 2021
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
June 24, 2021
Study did not meet primary endpoint of Total Improvement Score (TIS) at Week 28Additional findings included nominally significant improvements in TIS (p = 0.0302) and CDASI (p = 0.0166) depending on t...
June 21, 2021
In this article we are going to use hedge fund sentiment as a tool and determine whether Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) is a good investment right now. We like to analyze hedge fund...
June 18, 2021
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
June 12, 2021
Corbus Pharmaceuticals Holdings, Inc. ( NASDAQ:CRBP ) has not performed well recently and CEO Yuval Cohen will probably...
June 3, 2021
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
June 2, 2021
Dogecoin (CRYPTO: DOGE) is the perfect tool for people who love casinos. With its rocket ship-style price movements and nary a fundamental factor tethering the cryptocurrency to any price, investors ...
Next page